Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11527 posts found.

US panel supports accelerated approval for Intercept’s trial drug for rare liver condition

April 8, 2016 Medical Communications, Research and Development, Sales and Marketing Intercept Pharmaceuticals, PDUFA, US FDA, liver disorder, rare disease

Intercept Pharmaceuticals (Nasdaq: ICPT) said a US Food and Drug Administration (FDA) advisory committee has recommended accelerated approval for its …
News

FTC launches tool to help mobile health app developers determine applicable regulations

April 8, 2016 Medical Communications, Sales and Marketing FDA, FTC, apps, health, health apps, regulation

The US Federal Trade Commission has created a new web-based tool for developers of health-related mobile apps to help them …
News

Vectura to get $10 million milestone as Hikma files ANDA for generic copy of GSK’s asthma drug

April 8, 2016 Medical Communications, Research and Development, Sales and Marketing

Vectura Group (LSE: VEC) on Friday said it is set to receive $10 million in milestone payments from partner Hikma …
News

Boehringer Ingelheim’s Giotrif gets Europan regulatory backing in another lung cancer indication

April 7, 2016 Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, European Commission, giotrif, lung cancer

German drugmaker Boehringer Ingelheim on Thursday said European regulators have granted marketing rights for its non-small cell lung cancer (NSCLC) …
News

Incyte buys rights to Eli Lilly’s Ruxolitinib; shares jump

April 7, 2016 Research and Development, Sales and Marketing Eli Lilly, Incyte, Licencing, M&A, MA, Novartis

Shares in Incyte Corp (Nasdaq: INCY) soared to close up over 11.5% Wednesday as the company said it has purchased …
News

Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup

April 7, 2016 Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire

Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …
News

Allergan to partner with Heptares in Alzheimer’s disease collaboration

April 7, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Alzheimer's, Heptares, R&D, collaboration, commercialisation, h1, h4, neurological disorders, partnership, research and development, treatments

Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan (NYSE:AGN) has announced a new …
News

Novartis receives EU approval for blood disorder treatment in children

April 7, 2016 Research and Development, Sales and Marketing EMA, EU, ITP, Novartis, Revolade, approval, blood disorder, children, chronic itp

Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …
News

5 things to know about the Pfizer/Allergan inversion collapse

April 6, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 5, 5 things, Allergan, Pfizer, collapse, inversion, reasons

The end came very quickly for the Pfizer/Allergan $160 billion deal once the US Treasury Department announced a new set …
Feature

Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million

April 6, 2016 Business Services, Research and Development, Sales and Marketing Cancer, J&J, JJ, M&A, MA, Tesaro, drug, licence agreement, research

Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) …
News

Allergan, Pfizer confirm termination of $160 billion merger

April 6, 2016 Business Services, Research and Development, Sales and Marketing

Botox maker Allergan Plc (NYSE:AGN) and US pharma giant Pfizer (NYSE: PFE) on Wednesday confirmed they have terminated the merger …
News

Pfizer to call off $160 billion merger with Allergan

April 6, 2016 Business Services, Research and Development, Sales and Marketing Allergan, Pfizer, deal, legal, merger and acquisition, regulation

US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: …
News

Merck receives CE Mark approval for new liquid biopsy test for colorectal cancer

April 6, 2016 Medical Communications, Research and Development, Sales and Marketing CE Mark, Merck, biomarker, biopsy, colorectal cancer, liquid biopsy, ras, sysmex inostics

Merck (ETR: MRK) has announced that their new liquid biopsy RAS biomarker test for metastatic colorectal cancer, developed in collaboration …
News

Valeant’s ad hoc committee closes chapter on Philidor controversy

April 5, 2016 Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, ad hoc, ad hoc committee

Valeant (NYSE: VRX) has announced that the ad hoc committee of the board of directors has finished its review of …
News

Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial

April 5, 2016 Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib

Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …
News
The Gateway to Local Adoption Series

Latest content

Scots neonatal innovations target hearing loss and earlier care

August 28, 2026

FDA grants De Novo authorisation to light-filtering device for migraine

August 28, 2026

Southgate opens Innovation Lab for logistics and fulfilment development

August 27, 2026

Bioptimus partners with Cancer Research Horizons to expand AI cancer data set

August 27, 2026

Agentis Health Group acquires Clinical Pharmacist Solutions

August 26, 2026